Jubilant Pharmova to Raise 800 cr via Maiden Bond Issue

What happened

Jubilant Pharmova is raising 800 crore through its first local bond issue, with a 400 crore base issue and an equal greenshoe option, which is an extra allotment option. The bonds have a three-year tenure with indicative pricing around 8.50%.

Confirmed

Global impact / market context

This is the company's first time borrowing from the local bond market, which means it is widening its funding sources beyond banks. The stated use for capital spending and expansion suggests new investment, and the roughly 8.50% interest cost will add to expenses.

Analyst inference

Mutual funds and asset managers are expected to buy most of the bonds because the three-year maturity fits their typical holding periods. Final bidding is due later this week, so the actual price and demand will show how willing local bond investors are to lend to this drug maker.

Analyst inference

What to watch

1. Final bidding for the bonds is expected later this week, and the actual pricing will show whether the roughly 8.50% indicative level holds or borrowers must pay more. Confirmed
2. How much of the 800 crore is actually sold matters, because the 400 crore greenshoe option, which is an extra allotment, may not be fully used by buyers. Analyst inference
3. Watch later company updates on how the borrowed money is spent on capital spending and expansion, since delays could leave the firm paying interest without added revenue. Analyst inference

Evidence

• Original source link unavailable